Therefore, our study proposed a novel mechanism of breast cancer chemoresistance and suggested that BAG2 and mutant p53 aggregates might be potential clinical markers for identifying a subgroup of patients who are sensitive to IPI-504. This evidence concerns the gene TP53 and breast carcinoma.